# Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial

> **NCT02181101** · PHASE3 · COMPLETED · sponsor: **Ludwig-Maximilians - University of Munich** · enrollment: 3754 (actual)

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** FEC-DocGemzar adjuvant chemotherapy
- **DRUG:** FEC-Doc adjuvant chemotherapy
- **DRUG:** Zoledronic acid i.v. 2 years
- **DRUG:** Zoledronic acid i.v. 5 years

## Key facts

- **NCT ID:** NCT02181101
- **Lead sponsor:** Ludwig-Maximilians - University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 3754 (ACTUAL)
- **Last updated:** 2014-07-03

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02181101

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02181101, "Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02181101. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*